These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 19155081)

  • 41. High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitis.
    Nagaki M; Iwai H; Naiki T; Ohnishi H; Muto Y; Moriwaki H
    J Infect Dis; 2000 Oct; 182(4):1103-8. PubMed ID: 10979906
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of infliximab in active SLE: a pilot study.
    Uppal SS; Hayat SJ; Raghupathy R
    Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.
    Mathurin P; Mendenhall CL; Carithers RL; Ramond MJ; Maddrey WC; Garstide P; Rueff B; Naveau S; Chaput JC; Poynard T
    J Hepatol; 2002 Apr; 36(4):480-7. PubMed ID: 11943418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score.
    Forrest EH; Evans CD; Stewart S; Phillips M; Oo YH; McAvoy NC; Fisher NC; Singhal S; Brind A; Haydon G; O'Grady J; Day CP; Hayes PC; Murray LS; Morris AJ
    Gut; 2005 Aug; 54(8):1174-9. PubMed ID: 16009691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone.
    Mathurin P; Abdelnour M; Ramond MJ; Carbonell N; Fartoux L; Serfaty L; Valla D; Poupon R; Chaput JC; Naveau S
    Hepatology; 2003 Dec; 38(6):1363-9. PubMed ID: 14647046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Model for end-stage liver disease score versus Maddrey discriminant function score in assessing short-term outcome in alcoholic hepatitis.
    Kadian M; Kakkar R; Dhar M; Kaushik RM
    J Gastroenterol Hepatol; 2014 Mar; 29(3):581-8. PubMed ID: 24117536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity.
    Colmenero J; Bataller R; Sancho-Bru P; Bellot P; Miquel R; Moreno M; Jares P; Bosch J; Arroyo V; Caballería J; Ginès P
    Gastroenterology; 2007 Feb; 132(2):687-97. PubMed ID: 17258719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis.
    Dominguez M; Miquel R; Colmenero J; Moreno M; García-Pagán JC; Bosch J; Arroyo V; Ginès P; Caballería J; Bataller R
    Gastroenterology; 2009 May; 136(5):1639-50. PubMed ID: 19208360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The amount of alcohol intake, upper gastrointestinal bleeding, acute renal failure and hepatic encephalopathy as the risk factors implied in the increase of patients with alcoholic hepatitis].
    Higuera-de la Tijera MF; Pérez-Hernández JL; Servín-Caamaño AL; Serralde-Zúñiga AE; Cruz-Palacios A
    Rev Gastroenterol Mex; 2009; 74(4):306-13. PubMed ID: 20423759
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk factors for mortality in patients with alcoholic hepatitis and assessment of prognostic models: A population-based study.
    Pang JX; Ross E; Borman MA; Zimmer S; Kaplan GG; Heitman SJ; Swain MG; Burak K; Quan H; Myers RP
    Can J Gastroenterol Hepatol; 2015 Apr; 29(3):131-8. PubMed ID: 25855876
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Three prognostic utility scales to determine early mortality in patients with alcoholic hepatitis in the General Hospital of Mexico].
    Higuera-de la Tijera MF; Pérez-Hernández JL; Serralde-Zúñiga AE; Servín-Caamaño AI; Cruz-Palacios A; Bernal-Sahagún F; Salas-Gordillo F
    Rev Gastroenterol Mex; 2010; 75(3):281-6. PubMed ID: 20959177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. C-reactive protein predicts short-term mortality in patients with cirrhosis.
    Cervoni JP; Thévenot T; Weil D; Muel E; Barbot O; Sheppard F; Monnet E; Di Martino V
    J Hepatol; 2012 Jun; 56(6):1299-304. PubMed ID: 22314431
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of MELD score and Maddrey discriminant function for mortality prediction in patients with alcoholic hepatitis.
    Monsanto P; Almeida N; Lrias C; Pina JE; Sofia C
    Hepatogastroenterology; 2013; 60(125):1089-94. PubMed ID: 23803373
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial.
    Moreno C; Langlet P; Hittelet A; Lasser L; Degré D; Evrard S; Colle I; Lemmers A; Devière J; Le Moine O
    J Hepatol; 2010 Dec; 53(6):1117-22. PubMed ID: 20801542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prognostic evaluation and management of alcoholic hepatitis.
    Rana R; Wang SL; Li J; Xia L; Song MY; Yang CQ
    Minerva Med; 2017 Dec; 108(6):554-567. PubMed ID: 28602070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.
    Mookerjee RP; Sen S; Davies NA; Hodges SJ; Williams R; Jalan R
    Gut; 2003 Aug; 52(8):1182-7. PubMed ID: 12865279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis.
    di Mambro AJ; Parker R; McCune A; Gordon F; Dayan CM; Collins P
    Hepatology; 2011 Apr; 53(4):1316-22. PubMed ID: 21400552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.